Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sun Pharma Advanced Research CoNSE:SPARC -6.09%49 Cyclically Adjusted PS Ratio is 19.44 as of Jul. 18, 2026, which is 27% below its 10-year median of 26.70. GuruFocus rates NSE:SPARC with a GF Score™ of 49/100 and a GF Value™ of ₹94.43 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 752 Drug Manufacturers companies, Sun Pharma Advanced Research Co ranks worse than 97.07% on this metric.
The historical rank and industry rank for Sun Pharma Advanced Research Co's Cyclically Adjusted PS Ratio or its related term are showing as below:
NSE:SPARC'
s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 10.31 Med: 26.7 Max: 56.29
Current: 19.48
During the past years, Sun Pharma Advanced Research Co's highest Cyclically Adjusted PS Ratio was 56.29. The lowest was 10.31. And the median was 26.70.
NSE:SPARC's Cyclically Adjusted PS Ratio is ranked worse than 97.07% of 752
companies
in the Drug Manufacturers industry
Industry Median: 1.995
vs NSE:SPARC: 19.48
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.
Sun Pharma Advanced Research Co's adjusted revenue per share data for the three months ended in Mar. 2026 was ₹57.101. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is ₹12.10 for the trailing ten years ended in Mar. 2026.
Shiller PE for Stocks: The True Measure of Stock Valuation
Sun Pharma Advanced Research Co (NSE:SPARC) Cyclically Adjusted PS Ratio Explanation
Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.
Sun Pharma Advanced Research Co Cyclically Adjusted PS Ratio Related Terms
Sun Pharma Advanced Research Co Cyclically Adjusted PS Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sun Pharma Advanced Research Co Cyclically Adjusted PS Ratio Chart
NSE:SPARC vs ZTS, UTHR: Cyclically Adjusted PS Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Sun Pharma Advanced Research Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sun Pharma Advanced Research Co Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sun Pharma Advanced Research Co's Cyclically Adjusted PS Ratio distribution charts can be found below:
* The bar in red indicates where Sun Pharma Advanced Research Co's Cyclically Adjusted PS Ratio falls into.
Sun Pharma Advanced Research Co Cyclically Adjusted PS Ratio Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted PS Ratio of 19.44 mean?
Sun Pharma Advanced Research Co (NSE:SPARC) has a Cyclically Adjusted PS Ratio of 19.44 as of Jul. 18, 2026. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Sun Pharma Advanced Research Co and its competitors. This is 27% below median its historical median of 26.70. Over the past decade, Sun Pharma Advanced Research Co's Cyclically Adjusted PS Ratio has ranged from 10.31 to 56.29. According to the industry distribution chart, Sun Pharma Advanced Research Co ranks #730 out of 752 companies in the Drug Manufacturers industry, placing it in the top 97.1%.
Is Sun Pharma Advanced Research Co's Cyclically Adjusted PS Ratio too high?
Sun Pharma Advanced Research Co's current Cyclically Adjusted PS Ratio of 19.44 is 27% below median its 10-year median of 26.70. Over the past 10 years, this metric has ranged from a low of 10.31 to a high of 56.29. The Drug Manufacturers industry median Cyclically Adjusted PS Ratio is 2.00. Sun Pharma Advanced Research Co's value of 19.44 is 874.4% above this industry median. Based on the distribution chart, Sun Pharma Advanced Research Co ranks #730 out of 752 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Sun Pharma Advanced Research Co has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sun Pharma Advanced Research Co's Cyclically Adjusted PS Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Sun Pharma Advanced Research Co ranks #730 out of 752 companies for Cyclically Adjusted PS Ratio. This places Sun Pharma Advanced Research Co in the lower half of its industry. The industry median Cyclically Adjusted PS Ratio is 2.00. Sun Pharma Advanced Research Co's value of 19.44 is 874.4% above this benchmark. Historically, Sun Pharma Advanced Research Co's own Cyclically Adjusted PS Ratio has ranged from 10.31 to 56.29 over the past decade. While the company's 10-year median is 26.70 vs. the industry median of 2.00, Sun Pharma Advanced Research Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PS Ratio for a Drug Manufacturers company?
The median Cyclically Adjusted PS Ratio among Drug Manufacturers companies is 2.00, based on 752 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sun Pharma Advanced Research Co's current Cyclically Adjusted PS Ratio of 19.44 is 874.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PS Ratio mean?
A high Cyclically Adjusted PS Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Sun Pharma Advanced Research Co and its competitors. For the Drug Manufacturers industry, the median Cyclically Adjusted PS Ratio is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sun Pharma Advanced Research Co's current Cyclically Adjusted PS Ratio is 19.44, which is 27% below median its own 10-year median of 26.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sun Pharma Advanced Research Co stock overvalued right now?
Based on GuruFocus' analysis, Sun Pharma Advanced Research Co (NSE:SPARC) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹94.43, compared to a current price of ₹235.20 — trading 149.1% above its estimated fair value. The current Cyclically Adjusted PS Ratio is 19.44, which is 27% below median its 10-year median of 26.70 and 874.4% above the Drug Manufacturers industry median of 2.00. Sun Pharma Advanced Research Co's overall GF Score™ is 49/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PS Ratio calculated?
Cyclically Adjusted PS Ratio is calculated from a company's financial statements. For Sun Pharma Advanced Research Co (NSE:SPARC), the current Cyclically Adjusted PS Ratio is 19.44 as of Jul. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sun Pharma Advanced Research Co (NSE:SPARC) Overvalued in 2026?
Based on GuruFocus' analysis, Sun Pharma Advanced Research Co stock appears to be overvalued.
The current stock price of ₹235.20 is trading 149.1% above its estimated GF Value™ of ₹94.43.
GuruFocus considers Sun Pharma Advanced Research Co to be Significantly Overvalued.
Key valuation signals for NSE:SPARC:
Cyclically Adjusted PS Ratio: 19.44 (27% below median its 10-year median of 26.70)
GF Value™: ₹94.43 vs. price of ₹235.20 (149.1% above fair value)
Industry Position: 874.4% above the Drug Manufacturers median (#730 of 752)
No single metric tells the full story. See the NSE:SPARC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sun Pharma Advanced Research Co Business Description
Sun Pharma Advanced Research Co Ltd is an Indian specialty and generic drug manufacturing company. The company has identified pharmaceuticals research and development as its only reportable segment. The company is focused on drug discovery in focused therapy areas such as cancer and anti-inflammatory treatments. The company considers merger and acquisition investment as a potential component of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities. It derives maximum revenue from India and also has its presence in other countries.
49GF Score
Get the complete analysis for NSE:SPARC
Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:SPARC has been successfully added to your 
